Sam Brusco, Associate Editor06.26.23
GE HealthCare will unveil its new SIGNA PET/MR AIR at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. The company will also showcase integration of its AIR technologies with the system, aiming to boost diagnostic precision, simplify treatment evaluation, and elevate patient comfort.
GE’s AIR technologies incorporated into SIGNA PET/MR AIR include AIR Coils for patient comfort, AIR Recon DL for MR image quality and scan time reduction, and MotionFree Brain for mitigating motion-related PET image degradation.
Using prostate-specific membrane antigen (PSMA)-targeted PET radiotracers with high-sensitivity PET and anatomical precision has the potential for precise diagnosis and staging/re-staging of prostate cancer. It can also help select patients for subsequent PSMA-targeted radioligand therapy.
SIGNA PET/MR AIR has a very sensitive Time-of-Flight (ToF) PET detector so clinicians can get a diagnosis more quickly, get insights into disease progression, and spot adverse effects in one scan. MotionFree Brain PET manages motion without external tracking devices, helping ensure consistent image quality in even the most challenging patients.
"The SIGNA PET/MR AIR system continues our legacy of delivering innovative technologies that address a comprehensive range of clinical diseases,” Jie Xue, president and CEO of MR at GE HealthCare told the press. “Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer's Disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring. We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
GE’s AIR technologies incorporated into SIGNA PET/MR AIR include AIR Coils for patient comfort, AIR Recon DL for MR image quality and scan time reduction, and MotionFree Brain for mitigating motion-related PET image degradation.
Using prostate-specific membrane antigen (PSMA)-targeted PET radiotracers with high-sensitivity PET and anatomical precision has the potential for precise diagnosis and staging/re-staging of prostate cancer. It can also help select patients for subsequent PSMA-targeted radioligand therapy.
SIGNA PET/MR AIR has a very sensitive Time-of-Flight (ToF) PET detector so clinicians can get a diagnosis more quickly, get insights into disease progression, and spot adverse effects in one scan. MotionFree Brain PET manages motion without external tracking devices, helping ensure consistent image quality in even the most challenging patients.
"The SIGNA PET/MR AIR system continues our legacy of delivering innovative technologies that address a comprehensive range of clinical diseases,” Jie Xue, president and CEO of MR at GE HealthCare told the press. “Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer's Disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring. We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”